"Advances in the Prevention and Treatment of Congenital Cytomegalovirus Infection" / Scott H. James, and David W. Kimberlin
Material type:
Continuing resourceISSN: 1531-698XSubject(s): Congenital cytomegalovirus | Antiviral therapy | Valganciclovir | Vaccine | Mother-to-child transmission
In:
Current opinion in pediatrics -- 2016, v. 28, 1, p. 81-5Summary: Purpose of review—Cytomegalovirus (CMV) is the most common cause of congenital infection in the world. Symptomatic infants are at increased risk of developing permanent sequelae, including sensorineural hearing loss (SNHL) and neurodevelopmental delay. Advances in the treatment and prevention of congenital CMV infection are a high priority nationally and globally.
Recent findings—In symptomatic infants, antiviral therapy with 6 months of oral valganciclovir (VGCV) improves hearing and neurodevelopmental outcomes. Strategies to prevent congenital or maternal CMV infections, including the use of CMV hyperimmune globulin (HIG) and development of a maternal vaccine, have yet to yield positive results.
Summary—The clinical significance of congenital CMV infection, developments in antiviral therapy, and efforts to prevent congenital disease are herein reviewed.
| Item type | Current library | Collection | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
Artículo de revista
|
Revistas y artículos | Non-fiction | PP (Browse shelf(Opens below)) | Available | 5719 |
PDF en biblioteca
Bibliografía: p. 7-9
Purpose of review—Cytomegalovirus (CMV) is the most common cause of congenital infection in the world. Symptomatic infants are at increased risk of developing permanent sequelae, including sensorineural hearing loss (SNHL) and neurodevelopmental delay. Advances in the treatment and prevention of congenital CMV infection are a high priority nationally and globally.
Recent findings—In symptomatic infants, antiviral therapy with 6 months of oral valganciclovir (VGCV) improves hearing and neurodevelopmental outcomes. Strategies to prevent congenital or maternal CMV infections, including the use of CMV hyperimmune globulin (HIG) and development of a maternal vaccine, have yet to yield positive results.
Summary—The clinical significance of congenital CMV infection, developments in antiviral therapy, and efforts to prevent congenital disease are herein reviewed.
There are no comments on this title.